《Assessment of maintenance oral Etoposide following induction chemotherapy with gemcitabine and cisplating in chemonaive extensive small cell lung cancer》.pdfVIP

Chinese-German Journal of Clinical Oncology October 2010, Vol. 9, No. 10, P569–P573 DOI 10.1007/s10330-010-0675-5 Assessment of maintenance oral Etoposide following induction chemotherapy with gemcitabine and cisplating in chemonaive extensive small cell lung cancer 1 1 2 3 Lobna R Ezz Elarab , Manal M Abdel Wahab , Menha Swellam , Zakaria Mostafa 1 Radiation Oncology Nuclear Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt 2 Biochemistry Department, Genetic Engineering and Biotechnology Research Division, National Research Center, Giza, Egypt 3 Abbasia Chest Hospital, Cairo, Egypt Received: 25 July 2010 / Revised: 2 August 2010 / Accepted: 25 August 2010 © Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2010 Abstract Objective: The aim of our study was to evaluate the response and tolerability to treatment when using gem- citabine-cisplatin combination (GC), followed by maintenance therapy of oral etoposide for non-progressive patients in trial to improve progression free survival and overall survival. Methods: Thirty nine patients with extensive small cell lung cancer 2 (SCLC) and ECOG ≤ 2 received 4 cycles of chemotherapy consisting of gemcitabine 1000 mg/m (day 1 and 8) cisplating 75 2 mg/m (day 1) every three weeks. Twenty seven non-progressive patients after 4 cycles of chemotherapy were randomized 2 either to receive oral etoposide 50 mg/m for consecutive 15 days every 3 weeks vs no therapy for three